Epithelial Cell Immortalization via Stasis Bypass and Telomerase Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for immortalizing human epithelial cells lack efficiency and accuracy in mimicking in vivo carcinogenesis, leading to the absence of reliable models for examining telomerase reactivation and immortalization processes, which are crucial for understanding cancer progression.
Innovation Solution
A method involving the direct targeting of tumor-suppressive senescence barriers in human epithelial cells using pathologically relevant agents, specifically by introducing polynucleotide constructs to bypass stasis and reactivate telomerase activity, allowing for the reproducible immortalization of cells without genomic errors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oncogenic agents are used to immortalize human epithelial cells, then immortalization can be achieved, but the cells acquire genomic errors and represent rare clonal lines
Solution Approach 1:
The immortalization process is divided into two distinct phases: first inducing stasis bypass through oncogenic agents, then separately inducing telomerase reactivation. This segmentation allows each step to be optimized independently, reducing the accumulation of genomic errors while achieving immortalization.
Solution Approach 2:
The patent performs preliminary action by first establishing stasis bypass conditions before inducing telomerase reactivation. This preliminary step prepares the cells in a controlled manner, allowing subsequent telomerase induction to occur in cells that have already overcome senescence barriers, thereby reducing the need for multiple rounds of oncogenic exposure.
2Reliability
If hTERT is overexpressed to immortalize cells, then immortalization is achieved, but the model does not reflect in vivo carcinogenesis and shows properties unlike normal or abnormal HMEC
Solution Approach 1:
The patent extracts the essential feature of immortalization (telomerase reactivation) from the complex process of carcinogenesis, while maintaining the physiological context of epithelial cells. By separating telomerase induction from other oncogenic transformations, the model captures the critical immortalization step without the confounding effects of multiple genomic alterations.
Solution Approach 2:
The patent applies local quality by inducing telomerase reactivation specifically in epithelial cells that have bypassed stasis, rather than uniformly overexpressing hTERT. This localized approach maintains the natural heterogeneity and progression characteristics of in vivo carcinogenesis while achieving immortalization.
3Reliability
If oncogenic viruses like HPV or SV40 are used, then immortalization can occur, but the models do not accurately reflect in vivo carcinogenesis mechanisms
Solution Approach 1:
The patent creates a universal model system that can be applied to study immortalization across different epithelial cell types and cancer contexts. By using controlled induction of stasis bypass followed by telomerase reactivation, the approach is adaptable to various cell types and can model different aspects of carcinogenesis without being limited to virus-specific mechanisms.
Data Source
AI summary
Methods for inducing non-clonal immortalization of normal epithelial cells by directly targeting the two main senescence barriers encountered by cultured epithelial cells. In finite lifespan pre-stasis human mammary epithelial cells (HMEC), the stress-associated stasis barrier was bypassed, and in post-stasis HMEC, the replicative senescence barrier, a consequence of critically shortened telomeres, was bypassed. Early passage non-clonal immortalized lines exhibited normal karyotypes. Methods of efficient HMEC immortalization, in the absence of “passenger” genomic errors, should facilitate examination of telomerase regulation and immortalization during human carcinoma progression, methods for screening for toxic and environmental effect on progression, and the development of therapeutics targeting the process of immortalization.